Breast cancer is one of the most common malignancies treated by radiation oncologists. Indications for radiation in patients with breast cancer are increasingly dependent on advances in surgery and systemic treatments and improved understanding of tumor biology. Recent clinical trials indicate a variety of fractionation regimens involving whole breast or partial breast treatment are equally effective in patients with early stage breast cancer. This educational session will review the latest evidence supporting hypofractionated and ultrashort hypofractionated treatment regimens as well as indications for post mastectomy and regional nodal irradiation. We will also discuss clinical scenarios where radiation may be withheld. Radiation techniques will be discussed. Lastly, novel systemic and targeted therapies are being rapidly approved in patients with breast cancer, and this session will increase awareness regarding potential interactions between radiation and these treatments.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents, medical and clinical physicists, radiation therapists, radiation dosimetrists, nurses and all other health professionals involved in the field of radiation oncology.
Upon completion of this activity, participants should be able to do the following:
- Discuss a variety of equally effective radiation treatment options for patients with early-stage breast cancer and determine the best option for the individual patient through shared decision making.
- Determine when and how to perform regional nodal irradiation.
- Determine the best radiation technique for delivering treatment to an individual patient.
Mylin A. Torres, MD, is employed by Emory University and has received compensation from Oncohealth and Varian as well as research/grant funding from Genentech, NCI, and Pfizer.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Refresher Course Planning Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.50 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.50 Certificate of AttendanceThis activity was designated for 1.50 AMA PRA Category 1 Credit™.